Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bacterial Protoplast-Derived Nanovesicles Carrying CRISPR/Cas9 Tools Efficiently Re-educate Tumor-Associated Macrophages for Cancer Immunotherapy

ABSTRACT: Bacterial Protoplast-Derived Nanovesicles Carrying CRISPR/Cas9 Tools Efficiently Re-educate Tumor-Associated Macrophages for Cancer Immunotherapy

PROVIDER: PRJNA1018484 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Bacterial Protoplast-Derived Nanovesicles Carrying CRISPR Cas9 Tools Efficiently Re-educate Tumor-Associated Macrophages for Cancer Immunotherapy

Project description:we developed an in vivo CRISPR-Cas9 genome editing system that targets tumor-associated macrophages (TAMs) via bacterial protoplast-derived nanovesicles (NVs) decorated with a pH-responsive PEG conjugated polymer and galactosamine-conjugated ligand

2023-09-20 | PXD045507 |

Bacterial Protoplast-Derived Nanovesicles Carrying CRISPR/Cas9 Tools Efficiently Re-educate Tumor-Associated Macrophages for Cancer Immunotherapy

Project description:To investigate the activation of tumor microenvirment, we used E.coli-derived nanovesicles to treat tumor-bearing mice and detected tumor tisssues by RNA-Seq.

2023-11-27 | GSE243428 | GEO

Project description:Bacterial Protoplast-Derived Nanovesicles Carrying CRISPR Cas9 Tools Efficiently Re-educate Tumor-Associated Macrophages for Cancer Immunotherapy

| PRJNA1018426 | ENA

Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy.

Project description:The CRISPR-Cas9 system offers substantial potential for cancer therapy by enabling precise manipulation of key genes involved in tumorigenesis and immune response. Despite its promise, the system faces critical challenges, including the preservation of cell viability post-editing and ensuring safe in vivo delivery. To address these issues, this study develops an in vivo CRISPR-Cas9 system targeting tumor-associated macrophages (TAMs). We employ bacterial protoplast-derived nanovesicles (NVs) modified with pH-responsive PEG-conjugated phospholipid derivatives and galactosamine-conjugated phospholipid derivatives tailored for TAM targeting. Utilizing plasmid-transformed E. coli protoplasts as production platforms, we successfully load NVs with two key components: a Cas9-sgRNA ribonucleoprotein targeting Pik3cg, a pivotal molecular switch of macrophage polarization, and bacterial CpG-rich DNA fragments, acting as potent TLR9 ligands. This NV-based, self-assembly approach shows promise for scalable clinical production. Our strategy remodels the tumor microenvironment by stabilizing an M1-like phenotype in TAMs, thus inhibiting tumor growth in female mice. This in vivo CRISPR-Cas9 technology opens avenues for cancer immunotherapy, overcoming challenges related to cell viability and safe, precise in vivo delivery.

| S-EPMC10830495 | biostudies-literature

Protoplast data: suberized exodermis is required for tomato drought tolerance

Project description:This experiment aimed to identify protoplast-induced genes in tomato seedling, for future use in single cell datasets.

2023-10-01 | GSE212404 | GEO

transcriptome profiling from a protoplast culture of arabidopsis thaliana-From protoplast to plant : transcrip...

Project description:ra03-03_protoplats - transcriptome profiling from a protoplast culture of arabidopsis thaliana - transcriptome profiling and comparison of 6 status of differentiation - protoplasts were extracted from plantlet cultivated during 2 weeks then placed in a culture midium which stimulate cell division. Protoplasts were harvested after 0, 24, 48, 96 or 168 hours of culture. Biological repeat has been done (experiments A and C) Keywords: time course

2007-06-20 | GSE7984 | GEO

Myelin nanovesicles characterization

Project description:Neurodegenerative diseases affect millions of people worldwide and the presence of various physiological barriers limits the accessibility to the brain and reduces the efficacy of various therapies. Moreover, improving the solubility, stability and release of the drug in specific brain regions and in particular target cells (neuron or microglia), are essential factor to develop an efficient and targeted therapy for the treatment of brain disorders. Extracellular vesicles, nanoparticles and artificial nanovesicles represent a promising tool for contrast brain diseases, thanks to their ability to deliver therapeutic molecules and overcoming the problems mentioned. In this study, for the first time, we generated artificial nanovesicles derived from brain tissue, which were preliminary evaluated as potential brain delivery system. The nanovesicles were produced from myelin extracted from the brain, called Myelin NanoVesicles (MyVes). MyVes produced have an average diameter of 100nm, negative zeta potential, spheroidal morphology, lipids and main proteins of the myelin sheath and exhibit good cytocompatibility. The MyVes, are able to load a drug/molecule and cross a blood brain barrier model, in addition, they targeted specific brain regions, white matter and are able to interact mainly with the microglia cell line. Therefore, we propose MyVes for white matter and microglia targeted delivery as a potential approach to counteract white matter microglia related diseases

2021-12-15 | PXD026282 | Pride

Proteomics of egg yolk nanovesicles

Project description:Egg yolk was diluted with PBS and nanovesicles were isolated through microfiltration and ultracentrifugation.

2022-12-07 | MSV000090860 | MassIVE

Employment of exosome-mimetic nanovesicles as a plasma adjuvant for cancer targeting through Golgi stress-associated ferroptosis

Project description:Plasma oncology is a promising therapeutic method that employs ionized gas to selectively target cancer cells. However, despite its efficacy in directly exposing external cancer cells to plasma, a stable delivery method through the circulatory system to internal cancer cells has yet to be developed. In this study, we revealed that bioinspired exosome-mimetic nanovesicles (EMs) can serve as a plasma adjuvant to enhance the anti-cancer effect. EM treatment increased the half-life of plasma reactive species such as nitrogen oxide in solution, thereby increasing the cytotoxicity towards cancer cells. Our syngeneic mice model experiment demonstrated that EM-treated plasma (EM-Plasma) inhibited in vivo cancer growth more efficiently than conventional plasma administration. Furthermore, we uncovered a molecular mechanism through which EM-Plasma selectively induces cancer cell death, namely, Golgi stress-associated ferroptosis. Our study provides a promising approach for the clinical application of plasma oncology in cancer treatment.

2024-05-03 | GSE231561 | GEO

Comparison of splicing tools

Project description:Comparison of splicing tools

| PRJNA675664 | ENA